Our company is a preeminent Manufacturer, Supplier and Exporter of Bortezomib Injections from Delhi. The Bortezomib Injections we make available are indicated in case of Multiple myeloma and Mantle cell lymphoma. We ensure that the Injections reach the buyers in excellent quality packaging options. Bulk orders of the Injections are processed by us as per the specific requirements of the buyers.

Indications :

• Multiple myeloma

• Mantle cell lymphoma

Dosage :

• Dosage in Previously Untreated Multiple Myeloma : Bortezomib is administered as a 3-5 second bolus IV injection in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 1. In Cycles 1-4, Bortezomib is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, Bortezomib is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib.
• Dosage in Relapsed Multiple Myeloma and Mantle Cell Lymphoma : Bortezomib (1.3mg/m²/dose) is administered as a 3-5 second bolus IV injection twice weekly for 2 weeks (Days 1, 4, 8 & 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, Bortezomib may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, & 22) followed by a 13-day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive doses of Bortezomib.
• Renal Impairment : Not Required.

Packing :

• 1 Vial of 2mg
• 1 Vial of 3.5mg

Our company is a preeminent Manufacturer, Supplier and Exporter of Bortezomib Injections from Delhi. The Bortezomib Injections we make available are indicated in case of Multiple myeloma and Mantle cell lymphoma. We ensure that the Injections reach the buyers in excellent quality packaging options. Bulk orders of the Injections are processed by us as per the specific requirements of the buyers.

Indications :

• Multiple myeloma

• Mantle cell lymphoma

Dosage :

• Dosage in Previously Untreated Multiple Myeloma : Bortezomib is administered as a 3-5 second bolus IV injection in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 1. In Cycles 1-4, Bortezomib is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, Bortezomib is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib.
• Dosage in Relapsed Multiple Myeloma and Mantle Cell Lymphoma : Bortezomib (1.3mg/m²/dose) is administered as a 3-5 second bolus IV injection twice weekly for 2 weeks (Days 1, 4, 8 & 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, Bortezomib may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, & 22) followed by a 13-day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive doses of Bortezomib.
• Renal Impairment : Not Required.

Packing :

• 1 Vial of 2mg
• 1 Vial of 3.5mg